Immunolocalization of Androgen receptor (AR) and steroid 5 alpaha-reductase type II (5 alpha-reductase type II) in canine prostate - Effect of antiandrogen, chlormadinone acetate (CMA) -

Acta Histochemica et Cytochemica

Volumn 33, Issue 3, 2000, Pages 223-229

  Murakoshi, Masanori ^a   Tagawa, Masashi ^a   Ikeda, Rie ^a   Nakayama, Takaharu ^a   Ishimura, Kazunori ^b  

^a Grelan Pharmaceutical Co Ltd   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

5 alpha reductase type II; Androgen receptor (AR); Benign prostatic hyperplasia (BPH); Canine; Chlormadinone acetate (CMA)

Indexed keywords

EID: 0033867187     PISSN: 00445991     EISSN: None     Source Type: Journal    
DOI: 10.1267/ahc.33.223     Document Type: Article

References (31)

1. Beato, M.: Gene regulation by steroid hormones. Cell 56; 753-762, 1989.
2. Brendler, C. B., Berry, S. J., Ewing, L. L., McCullough, A. R., Cochran, R. C., Standberg, J. D., Zirkin, B. R., Coffey, D. S., Wheaton, L. G., Hiler, M. L., Niswender, G. D., Bordy, M. J., Shaper, J. H., Scott, W. W. and Walsh, P. C.: Spontaneous benign prostatic hyperplasia in the beagle. The relationship between age, serum hormone levels, and the morphology and function of the canine prostate. J. Clin. Invest. 71; 1114-1123, 1983.
3. Carson-Jurica, C. A., Schrader, W. T. and O'Malley, B. W.: Steroid receptor family: structure and functions. Endocr. Rev. 11; 201-220, 1990.
4. Chang, C. and Kokontis, J.: Identification of a new member of the steroid receptor suprer-family by cloning and sequence analysis. Biochem. Biophys. Res. Commun. 155; 971-979, 1988.
5. Cohen, S. M., Werrmann, J. G., Rasmusson, G. H., Tanaka, W. K., Malatesta, P. F., Prahalada, S., Jacobs, J. G., Harris, G. and Nett, T. M.: Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate. Suppression of prostate DHT correlated with prostate regression. Prostate 26; 55-71, 1995.
6. Forti, G., Salenrno, R., Moneti, G., Zoppi, S., Fiorelli, G., Martini, T., Natali, A., Castanitini, A., Serio, M., Martini, L. and Motta, M.: Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostate hyperplasia. J. Clin. Endocrinol. Metab. 68; 461-468, 1989.
7. Gloyna, R., Siiteri, P. K. and Wilson, J. D.: Dihydrotestosterone in prostatic hypertrophy. II. The formation and content of dihydrotestosterone in the hyperplastic canine prostate and the effect of dihydrotestosterone on prostate growth in the dog. J. Clin. Invest. 49; 1746-1753, 1983.
8. Gormley, G. J., Stoner, E., Bruskewita, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., Vaughan, E. D., Pappas, F., Tayler, A., Binkowitz, B. and Group, T. F. S.: The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 327; 1185-1191, 1992.
9. Graham, R. C. and Karnovsky, M. J.: The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney. J. Histochem. Cytochem. 14; 291-302, 1966.
10. Harada, M., Kinoshita, Y., Moriyama, M., Kondo, I., Nakahashi, M., Kumagai, H., Sasaki, K. and Hosaka, M.: Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA). Prostate 25; 147-155, 1994.
11. Huang, J. K., Bartsch, W. and Voit, K. D.: Interaction of an antiandrogen (cyproterone acetate) with the androgen receptor system and its biological action in the rat ventral prostate. Acta Endocrinol. 109; 569-576, 1985.
12. Isaacs, J. T. and Coffey, D. S.: Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia. Endocrinology 108; 445-453, 1981.
13. Ito, Y., Kurosawa, I., Yamanaka, H., Koya, A., Imai, K., Kasaku, N. and Shida, K.: The mechanism of antiandrogenic action of chlormadinone acetate. Hinyoka Kiyo 68; 537-552, 1977. (in Japanese)
14. Lowseth, L. A., Gerlach, R. F., Gillett, N. A. and Muggenburg, B. A.: Age-related changes in the prostate and testes of the beagle dog. Vet. Pathol. 27; 347-353, 1990.
15. Miyamoto, T., Tsuruo, Y., Kagawa, S., Yokoi, H. and Ishimura, K.: Immunolocalization of steroid 5 alpha-reductase type II in human prostate, seminal vesicle and vas deferences. Light and electron microscopic immunohistochemistry. Acta Histochem. Cytochem. 29; 29-37, 1996.
16. Mizokami, A., Masai, M., Shimazaki, J. and Sugita, A.: Production of polyclonal antibody against human androgen receptor and immunohstochemical study of human androgen receptor in prostatic tissues. Jpn. J. Urol. 83; 1801-1807, 1992.
17. Murakoshi, M., Inada, R., Tagawa, M., Mizokami, A. and Suzuki, M.: Immunohistochemical study of androgen receptor in rat prostatic hyperplasia. Acta Histochem. Cytochem. 27; 75-80, 1994.
18. Murakoshi, M., Inada, R., Tagawa, M., Suzuki, M., Mizokami, A. and Watanabe, K.: Histopathological and immunohistochemical studies in the rat venrtal prostate. J. Toxicol. Pathol. 6; 55-64, 1993.
19. Murakoshi, M., Inada, R., Tagawa, M., Mizokami, A., Suzuki, M. and Watanabe, K.: Histopathological and immunohistochemical studies in the rat dorsolateral prostate. J. Toxiol. Pathol. 7; 387-395, 1994.
20. Murakoshi, M., Inada, R., Tagawa, M., Makino, M., Suzuki, M., Mieda, M., Honma, S. and Yamanaka, H.: Inhibitory influence a new steroidal antiandrogen, TZP-4238, on prostatic hyperplasia in the beagle dog. Acta Pathol. Jpn. 42; 151-157, 1992.
21. Okada, K., Onishi, K., Yoshida, O., Sudo, K., Kawase, M. and Nakayama, R.: Study of the effect of antiandrogen (Oxendolone) on experimentally induced canine prostatic hyperplasia. Urol. Res. 16; 67-72, 1988.
22. Prahalada, S. R., Keenan, K. P., Hertzog, P. R., Gordon, L. R., Peter, C. P., Soper, K. A., Zwinten, M. J. and Bokelman, D. L.: Qualitative and quantitative evaluation of prostatic histomorphometry in rats following chronic treatment with finasterid, 5-alpha-reductase inhibitor. Urology 43; 680-685, 1994.
23. Russell, D. W. and Wilson, J. D.: Steroid 5 alpha-reductase. Two genes/two enzymes. Ann. Rev. Biochem. 63; 25-61, 1994.
24. Sar, M., Lubahn, D. B., French, F. S. and Wilson, E. M.: Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 127; 3180-3186, 1990.
25. Takezawa, Y., Fukabori, N., Yamanaka, H., Mieda, M., Honma, S., Kushitani, M. and Hamataki, N.: Effects of the new steroidal antiandrogen TZP-4238 on hormone-induced canine prostatic hyperplasia. Prostate 21; 315-329, 1992.
26. Takezawa, Y., Ito, K., Suzuki, K., Fukabori, N., Yamanaka, H., Honma, S., Mieda, M., Hamataki, N. and Kushitani, M.: Effect of a new steroidal antiandrogen, TZP-4238, on spontaneously developed canine benign prostatic hyperplasia. Prostate 27; 321-328, 1995.
27. Tunn, S., Hochstrate, H., Habenicht, V. E. and Kerg, M.: 5 alpha-reductase activity in epithelium and stroma of prostates from intact and castrated dogs treated with androstandiene, the aromatase inhibitor 1-methyl-1,4-androstadiene-3,17-dione, and cyproterone acetate. Prostate 12; 243-253, 1988.
28. Wang, L. G., Lie, X. M., Kreis, W. and Budman, D. R.: Down-regulation of prostate-specific antigen (PBS) expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promotor of the PSA gene in LNCap cells. Cancer Res. 57; 714-719, 1997.
29. Wilson, J. D.: The pathogenesis of benign prostatic hyperplasia. Am. J. Med. 68; 745-756, 1980.
30. Zamboni, L. and DcMartino, C.: Buffered picric acid formal-dehyde. A new rapid fixation for electron microscopy. J. Cell Biol. 35; 148A, 1967.
31. Zirkin, B. R. and Stranberg, J. D.: Quantative changes in the morphology of the aging canine prostate. Anal. Rec. 208; 207-214, 1984.